HSBC upgrades CSPC stock rating citing growth in innovative drugs

HSBC upgraded CSPC Pharmaceutical Group (1093:HK) to Buy with a new price target of HK$9.50, citing a recovery in performance with double-digit sales and profit growth, as well as potential licensing deals and a positive readout for drug SYS6010. Analysts project an 11% net profit CAGR from 2025-2027 and have increased net profit estimates by 7-19% for 2025-2026. Despite a 65% year-to-date rally, CSPC's valuation remains attractive relative to domestic peers, suggesting further upside potential.

Analysis

HSBC analysts have upgraded CSPC Pharmaceutical Group Ltd. (1093:HK) to Buy from Hold, more than doubling the price target to HK$9.50 from HK$4.70, signaling strong conviction in the company's outlook. This revision is driven by a tangible recovery in performance, highlighted by quarter-on-quarter product sales growth of 12% and profit growth of 60%. The upgrade is further supported by CSPC's announcement on May 30 regarding three potential licensing-out deals, which indicate faster and more significant business development progress than previously anticipated by HSBC, alongside a positive clinical readout for its innovative drug SYS6010. Consequently, analysts have increased their net profit estimates for CSPC by 7-19% for the 2025-2026 period and now project an 11% compound annual growth rate in net profit from 2025 to 2027, stemming from expectations of higher business development income and improved operating cost controls. Despite a substantial year-to-date rally of approximately 65%, outperforming the Hang Seng China Enterprises Index's 37% increase, CSPC's stock trades at a price-to-earnings ratio of 15.5 times estimated 2025 earnings. This valuation is considerably lower than the domestic peers’ average of 25.6 times, suggesting that the stock remains attractively priced. HSBC foresees further upside potential, supported by anticipated new drug launches and an accelerated pace of business development with larger income scales.

Key Decisions for Investors

• Investors should consider the upgraded Buy rating and significantly increased price target as strong indicators of CSPC's enhanced growth prospects and potential for share price appreciation.
• The current valuation at 15.5 times estimated 2025 earnings, markedly below the domestic peer average, may present a compelling investment opportunity, even after the notable year-to-date stock performance.
• Key catalysts to monitor include the finalization and terms of the three potential licensing-out deals, continued positive clinical developments for new drugs like SYS6010, and evidence of sustained operating cost efficiencies impacting profit margins.